Transthyretin Amyloidosis ATTR Market Overview
The global Transthyretin Amyloidosis ATTR market was valued at USD 1.0 billion in 2024 and is expected to grow from USD 1.2 billion in 2025 to USD 3.5 billion by 2035, registering a CAGR of 11.7% during the forecast period from 2025 to 2035. Market growth is being driven by increasing awareness of ATTR, improved disease diagnosis, advances in diagnostic technologies, expanding treatment options, and growing investment in targeted therapies and gene therapy.
North America is expected to remain the dominant regional market, valued at USD 600 million in 2024 and projected to reach USD 1.8 billion by 2035. Europe is also experiencing steady expansion due to increased focus on innovative treatment modalities and specialized care, while Asia Pacific is expected to witness strong growth as awareness of rare diseases and access to advanced healthcare services improve.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=593992
Key Companies in the Transthyretin Amyloidosis ATTR Market
Pfizer
Teva Pharmaceutical Industries
Sobi
Boehringer Ingelheim
Bristol Myers Squibb
Alcon
Helsinn Healthcare
Eidos Therapeutics
Amgen
Janssen Pharmaceuticals
Cipla
Horizon Therapeutics
Alnylam Pharmaceuticals
Regeneron Pharmaceuticals
Ionis Pharmaceuticals
AstraZeneca
The Transthyretin Amyloidosis ATTR Market is experiencing significant development as improved awareness and screening enable earlier identification of the disease. Advances in non-invasive imaging, genetic testing, and other diagnostic methods are supporting better disease management. The treatment landscape is also evolving through disease-modifying therapies, RNA-based treatments, monoclonal antibodies, and emerging gene therapy approaches. Strategic partnerships between pharmaceutical and biotechnology companies are further supporting innovation and expanding access to treatment.
The market is segmented by type, treatment modalities, diagnosis method, stage of disease, and region. By type, the market includes Hereditary Transthyretin Amyloidosis, Wild-Type Transthyretin Amyloidosis, and Other Types. Treatment modalities include Pharmacological, Non-Pharmacological, and Gene Therapy. Diagnosis methods include Biopsy, Imaging Techniques, and Blood Tests, while disease stages comprise Asymptomatic, Mild Symptoms, Moderate Symptoms, and Severe Symptoms.
Recent Developments and Market Trends:
Increasing awareness of transthyretin amyloidosis is supporting earlier diagnosis and greater demand for specialized treatment.
Advanced imaging techniques and genetic testing are improving the identification and management of ATTR.
Wild-Type Transthyretin Amyloidosis represents a major market segment, supported by its association with aging populations.
RNA-based gene-silencing therapies are attracting increasing research and investment because of their potential to address disease mechanisms.
Gene therapy is emerging as a promising area for future ATTR treatment development.
Strategic collaborations between pharmaceutical and biotechnology companies are accelerating the development of next-generation therapies.
Personalized treatment approaches incorporating genetic profiling are creating new opportunities for improved patient management.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Transthyretin Amyloidosis ATTR Market.
Analyze market segmentation by type, treatment modalities, diagnosis method, stage of disease, and region.
Evaluate growth opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify leading companies and assess the competitive landscape of the ATTR market.
Examine the factors driving greater awareness, diagnosis, and treatment of transthyretin amyloidosis.
Understand emerging opportunities associated with RNA therapies, gene therapy, and targeted treatments.
Assess the impact of advanced diagnostic technologies and expanding healthcare access on future market development.
Future Outlook:
The Transthyretin Amyloidosis ATTR Market is expected to maintain strong growth through 2035 as awareness, diagnosis, and treatment options continue to improve. Increasing adoption of disease-modifying therapies, advances in genetic testing and imaging, and growing investment in RNA-based and gene therapies are expected to create significant opportunities. Expansion of specialized treatment centers and improved access to innovative therapies, particularly across emerging markets, should further support the long-term development of the ATTR market.
➤➤Explore Our Latest Related Reports:
